The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
- This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:
- - CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- - Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- - Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
- Industry Trends
1.2. Regulatory trends in brief
- Industry Analysis
2.2. Contract manufacturing - opportunities and threats
2.3. Quarterly mergers, acquisitions, and financing - Q1 2025
- Value Chain
3.2. API chemical
3.3. API biologics - protein and peptide
3.4. API biologics - cell, gene, vaccine, and virus
3.5. Commercial dose manufacturing and packaging
3.6. Clinical dose manufacturing and packaging
3.7. Analytical services
- About the Analyst
- About the Authors
- Contact the Publisher
Table 1: Contract service agreements
Table 2: Contract manufacturing: opportunities and threats - potentially positive
Table 3: Contract manufacturing: opportunities and threats - potentially negative
Table 4: Mergers, acquisitions, and financing - Q1 2025
List of Figures
Figure 1: FDA approvals by year, 2015-24
Figure 2: Deals by deal geography, by volume
Figure 3: Deals by deal geography, by volume
Figure 4: The contract manufacturing value chain
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Madrigal Pharmaceuticals
- Verona Pharma Inc
- Eli Lilly
- Mesoblast Inc
- Altor Bioscience
- Bristol Myers Squibb
- Syndax Pharmaceuticals
- Idorsia Pharmaceuticals US Inc
- Adaptimmune Therapeutics Plc
- Klinge Pharma GmbH
- InflaRx NV
- Galapagos NV
- Secretome Therapeutics
- MiRecule Inc
- JCR Pharmaceuticals Co Ltd
- SanBio Co Ltd
- Midas Pharma GmbH
- Northway Biotech UAB
- Mallia Therapeutics GmbH
- Lyndra Therapeutics Inc
- CymaBay Ireland Limited
- Sillajen Biotherapeutics
- AGC Biologics Inc
- Almac Group Ltd
- Cardinal Health Inc
- Dottikon Exclusive Synthesis AG
- Emergent BioSolutions Inc
- Excella GmbH & Co KG
- KBI Biopharma Inc
- Kennet Bioservices Ltd
- Lek Pharmaceuticals dd
- Lonza Biologics Plc
- Lonza Biologics Porrino SL
- Lonza Group Ltd
- Daiichi Sankyo Inc
- Lyophilization Services of New England Inc
- Novo Nordisk AS
- Organon & Co
- Patheon NV
- Quotient Sciences Ltd
- Renaissance Lakewood LLC
- SEQENS
- Sharp Packaging Services
- University of Tennessee Plough Center for Sterile Drug Delivery
- Veranova LP
- Vetter Pharma-Fertigung GmbH & Co KG
- WuXi Biologics Co Ltd
- InflaRx NV
- Biocina Pty Ltd
- Synthon International Holdings BV
- Jabil Inc
- Lantheus Holdings Inc
- MSD International GmbH
- AGC Pharma Chemicals Europe SLU
- Carbogen Amcis AG
- Kyowa Hakko Bio Co Ltd
- Charles River Laboratories International Inc
- Cytovance Biologics Inc
- PolyPeptide Group AG
- ReciBioPharm
- BioCentriq Inc
- Orchestra Life Sciences Co LLC
- NecstGen BV
- Pan Cancer T BV
- Patheon NV
- Rentschler Biopharma SE
- SCT Cell Manufacturing sro
- CCRM Nordic AB
- Touchlight Genetics Ltd
- Viralgen Vector Core SL
- International Isotopes Inc
- Novel Laboratories Inc
- PSM GmbH
- Recipharm AB
- Upperton Ltd
- Jupiter Neurosciences Inc
- Almac Group Ltd
- Chemika Pty Ltd
- Solvias AG
